MRK vs DVA
By Alex · Tickerpine
Merck & Co., Inc. vs DaVita Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DVA |
|---|---|---|
| Price | $148.78 | $178.47 |
| Market cap | $367.07B | $11.39B |
| P/E ratio | 119.0 | 15.1 |
| ROE | 6.96% | 88.48% |
| Profit margin | 4.77% | 6.05% |
| Revenue growth | 5.10% | 5.20% |
| Dividend yield | 2.29% | — |
| Beta | 0.23 | 0.83 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DVA in plain English
- MRK is the bigger company — about 32.2× the market cap of DVA.
- DVA is cheaper on earnings (P/E 15.1 vs 119.0).
- DVA earns a higher return on equity (88% vs 7%).
- DVA is growing revenue faster (5% vs 5%).
- MRK pays a dividend (2.29%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DVA return calculator
See what $1,000 in DaVita Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.